IV International Conference

Krzysztof Landa, M.D.

Krzysztof Landa is the CEO of HTA Audit, a company dealing with the quality of HTA (Health Technology Assessment) reports directed to authorities and public institutions in Poland and the President of the Watch Health Care Foundation. From 2010 till 2011 he was President of Central & Eastern European Society of Technology Assessment in Health Care. In 2006-2007 Dr Landa was the Director of Drug Policy Department in the Central Office of National Health Fund. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology Assessment International (HTAi) and performed his duties till mid 2007. He was the Chairman of the LOC of the first HTAi Annual Meeting 2004, held in Krakow, Poland.
Dr Landa is a graduate of the University School of Medicine and received his management education at the Postgraduate School of Public Health of Jagiellonian University in Krakow. Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Dr Landa organized many national and international HTA workshops and conferences.
In years 2006 – 2008 Dr Landa provided consultancy for the Serbian Ministry of Health. He was team leader of the World Bank project aimed at introduction of HTA in Serbia, implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency.

Mark Parker, MSc

Mark Parker is Senior Economic modeller for the University of Liverpool Health Economic Unit, Liverpool Cancer Trials Unit and Technical director of Evaluate Econ Ltd, UK. Early background was in software and electronic engineering (University of Manchester) and real time Digital Signal Processing, along with RF design. Completed the MSc in Health Economics at the University of York, UK (2009). Currently PhD submission pending in Health Economic Modelling at the University of Liverpool. These roles have mostly involved developing models and evidence based messages for a wide range of disease areas for global value dossiers and HTA submissions to NICE, SMC and CVZ, along with internal decision-making. Working with GSK (vaccines), Sanofi Aventis (Diabetes), Wirral Primary Care Trust (Real world data validation), CHAMPS (weight management interventions) and Shire (biological in a chronic condition).
Experience in a vast range of disease areas and population modelling, with a strong educational background in economics, software development, distributed systems and computation, Artificial Intelligence (1st, BSc Economics and Computer Science, UoL). Applying these skills to develop evidence based value arguments for Health Technology Assessment. This training, education and experience provide the means to apply the world’s most advanced techniques to solve complex problems in a methodical, transparent and comprehensible way, with a core focus on knowledge transfer. Enjoys a wide range of water, snow and motor sports.

Magdalena Wladysiuk, M.D.

Magdalena Wladysiuk is a president and owner of HTA Consulting. She is the president of the Central & Eastern European Society of Technology Assessment in Health Care (CEESTACH).
She is a medical doctor with MBA in Technology Management. She is one of the authors of 100 HTA reports for industry and public health insurance and financial analyses developed since 2001 (some are in Polish and some are available in English). From 2006 till 2008 she provided consultancy services for the Serbian Ministry of Health (MoH) in respect to evidence based basic benefit package, design and feasibility study on different models of HTA Agency in Serbia and quality of best practice guidelines. In addition she was also involved in the Evidence Based Heath care (EBHC) development, HTA systemic implementation, in-depth training of Serbian HTA analysts and development of 3 country specific HTA reports.
Currently she closely works with MoH Poland counterparts and private sector, develops strategic planning, economic analysis, health promotion, standards, cost reduction and clinical/health information systems.
Magdalena Wladysiuk is involved in promotion of HTA in the region of CEE which resulted in international cooperation in education and HTA. She organized many national and international HTA workshops and conferences and she was a speaker at most of them.

Tarik Catic, MSc

Tarik Catic is founder and president of ISPOR Bosnia and Herzegovina Regional Chapter and president of Section for pharmacoinformatics and pharmacoeconomics at Pharmaceutical Society of Federation of Bosnia and Herzegovina. He graduated at Faculty for Pharmacy in Sarajevo, and since 2010 he holds master degree in health economics and pharmacoeconomics, PompeuFabra University, Barcelona, Spain.
He is employed in pharmaceutical industry working on position of product manager in area of CNS, rheumatology, osteoporosis, anti-infectives and oncology portfolio, experienced in pharmaceutical marketing, drug regulatory, market access, clinical trials, and was team leader in Adriatic region. He was included in different projects in area of business development, market potential analysis and evaluation and portfolio development. Tarik is permanent member of ISPOR HTA Round table for Europe.
As ISPOR BH president Tarik initiated and actively participated in several projects like translation and adoption of ISPOR Book of Terms, ISPOR Good research practices, ISPOR distance learning modules, he was firs chief editor of ISPOR BH Newsletter. Tarik participated as organizing committee member for pharmacoeconomic conferences, congresses and scientific meetings. He was team leader for development of ISPOR BH learning modules for basic pharmacoeconomic course and is lecturer in this course program as part of continuing medical education. Tarik published a several scientific papers published in indexed scientific journals, he participated in numerous local and international congresses and conferences as invited lecturer and poster presenter. He actively works on promotion of pharmacoeconomics and education in this field and HTA implementation in decision making in health care in Bosnia and Herzegovina.

Vanesa Benkovic, MSc Pharm

Senior consultant HTA, HE and Research
Croatian Society for Pharmacoeconomics and Health Economics, Zagreb, Croatia
Vanesa Benkovic, graduated her masters study as manager in health and health services at Medical Faculty, University of Zagreb. She is currently finishing her PhD thesis on health inequalities at Faculty of Philosophy, Sociology Dpt. University of Zagreb.
Vanesa graduated several educations in field of pharmacoeconomics, health economics and advanced modeling in HTA in France and Austria. She received Open Society scholarship at Global Health Economics project by European University of StPetersburg, Russia. She teaches pharmacoeconomics and health economics at Faculty of Medicine, Faculty of Pharmacy University of Zagreb, and health statistics at European University of StPetersburg GHE courses. Her field of work includes extensive list of health economic analysis for drugs, devices, technologies and cost of illness studies in Croatia, Slovenia and Bosnia and Herzegovina, as well as research methodology for various EU JA projects such as Urban health centers Europe and Cross border patient registries initiative (PARENT). She also designs and performs market and scientific research in health. Her latest engagements include health business intelligence for a World Bank project for Croatian Ministry of Health and strategic consultancy both for pharmaindustry and budget holders.
She publishes papers in area of research methodology, public health, pharmacoeconomics and health economics. Currently Vanesa is setting up business including IT applications for polypharmacy.

Tanja Novakovic, MSc Pharm

Tanja Novakovic M.Sc. Pharm is the president of the Pharmacoeconomics Section within the Pharmaceutical Association of Serbia. She is founder of the ISPOR Serbian chapter and between 2007 and 2009 its vice president. Since 2001 she has been working in Galenika a.d., a pharmaceutical company, as a product manager for drugs of the central nervous system.
Tanja Novakovic is a graduate of the University of Belgrade, Faculty of Pharmacy finishing her postgraduate studies at the Faculty of Pharmacy at Ghent University in Belgium. She is the author of the “Handbook for pharmacoeconomic evaluations”, the first such publication in the field of pharmacoeconomics in the Serbian language. Through the Pharmacoeconomics Section she is constantly increasing awareness of health economics, pharmacoeconomics and the importance of Health Technology Assessment (HTA). She is active in shaping healthcare policy, writing the first Guidelines for pharmacoeconomic evaluations for Serbia. She was also co author in one of the three HTA analyses first completed in Serbia, and was engaged to lead a group of experts to define all existing elements of basic benefit package in Serbia (World Bank/Ministry of Health of Serbia projects).
Tanja has organized and presented in many national meetings and international conferences which have resulted in international cooperation in education and the developing of pharmacoeconomics and HTA in Serbia.

Janko Samardzic, M.D., PhD, spec.

Janko Samardzic is a specialist in Clinical Pharmacology at the Institute of Pharmacology, Clinical Pharmacology and Toxicology in Belgrade. He is teaching at the Medical Faculty, University of Belgrade, Serbia. Dr Samardžić has a master degree in Experimental Pharmacology and PhD in the field of Medical Pharmacology. He completed postgraduate courses in the pharmaco-epidemiology and clinical trials at Erasmus University Medical Center Rotterdam, The Netherlands. Currently he holds the position of Chief for Pharmacoeconomics in Republic Health Insurance Fund.
As a researcher, Dr Samardžic is a member of the Science Project by the Ministry of Education, Science and Technological Development, Republic of Serbia. He is a member of Serbian Pharmacological Society, Austrian Pharmacological Society and European Colleague of Neuropsycho- pharmacology (ECNP). Also, he is an expert for preclinical and clinical drug evaluations at the regional Agencies for Medicines and Medical Devices.
Dr Samardzic has extensive experience and expertise in Pharmacology, he is the author of a large number of peer reviewed papers, and also a regular speaker at international medical and pharmaceutical workshops and conferences.

Eldon Spackman, PhD

Eldon Spackman is a Research Fellow in the Team for Economic Evaluation and Health Technology Assessment at the Centre for Health Economics, University of York. He joined the Centre for Health Economics in 2010. He holds a BA (2002) and MA (2006) in Economics from the University of Calgary and a PhD (2009) from the Pharmaceutical Outcomes and Policy Program at the University of Washington.
His research interests include methods for incorporating uncertainty in the decision making framework, the effects of investment and irrecoverable costs in HTA and assessments of screening and diagnostics. Eldon has recently worked on empirical estimates of the UK cost-effectiveness threshold and methods to support the UK Department of Health on the implementation of value based pricing. He has also been involved in model development or clinical trials in a number of disease areas including Alzheimer’s disease, asthma, psoriatic arthritis, depression and prostate cancer.
He is an associate editor for BMC Public Health and a member of the PSSRU unit cost advisory group. Eldon is also a member of the Technology Appraisal Committee for the National Institute for Health and Clinical Excellence (NICE) and supports method development as a member of NICE’s Decision Support Unit.

Professor York F. Zöllner

York F. Zöllner is professor of health economics at Hamburg University of Applied Sciences since March 2010. As such, he will his do share in 'producing' the next generation of skilled young health economics experts. Likewise, he will strive to make his own contribution to research and public health by conducting meaningful analysis in the fields of cost-of-illness, cost-effectiveness of healthcare interventions, and equity issues. Prior to rejoining academia, he was Research Director with a contract research organization in the HEOR and P&R space. Previously, he was Director of Global Health Economics with a mid-sized European pharmaceutical company, where he was accountable for the P&R status of the worldwide product portfolio, ranging from conception of late-phase clinical trials to hands-on payer submissions at national level. York is member of the editorial board of the Journal of Medical Economics and regular peer reviewer for a number of other journals.

Brian Godman, PhD

Brian Godman is researcher at Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden and also positions with Mario Negri Institute for Pharmacological Research, Milan, Italy and Prescribing Research Group, Liverpool University, United Kingdom. Brian Godman is actively working with health authorities and health insurance companies across Europe, South America, UAE (Abu Dhabi) and USA, evaluating the impact of measures to enhance both the quality and efficiency of prescribing of both new and existing products. This includes Serbia. Prior to active research, Brian spent thirteen years in European and Global healthcare consultancy undertaking numerous projects including appraising current and planned reforms to enhance the quality and efficiency of prescribing, their transferability, and implications for all key stakeholders groups. It also included evaluating developments in the pricing and reimbursement of drugs and their influence on product development and market access strategies. He is author of 37 scientific journals.

Predrag Djukic, M.D., MSc

Since 2006 Predrag is working on the implementation of the health sector reform projects of the Ministry of Health of Serbia that are financed from the World Bank loans. He held both managerial and expert positions in the implementation of those projects. Furthermore, Predrag also provided consultancy services in Serbia and abroad. His expertise is in Health Financing, with focus on provider payment mechanisms, including diagnosis related groups in particular. Other main interests include Health Technology Assessment both in methodological sense and in the sense of institutionalization of HTA in Serbia.
Predrag is a medical doctor with a Masters degrees in Clinical Anatomy from the University of Belgrade School of Medicine and in International Health Care Management, Economics and Policy from the Bocconi University in Milan, Italy. He is a founding member of ISPOR Serbia and has a close association with CEESTAHC.

Ruth Lopert, M.D.

Ruth Lopert, a public health physician and pharmacoeconomist, is Principal Adviser at the Australian Therapeutic Goods Administration (TGA). In 2011-12 she was Visiting Professor in Health Policy at George Washington University (GW), and from 2008-2011 was the chief medical officer at the TGA. In 2006-07 she held a Harkness Fellowship in Health Policy and in 2005-06was director of Pharmaceutical Policy in the Australian Department of Health, responsible for developing policy to support sustainability of Australia’s drug coverage program. She had previously served as both director of the program, andclinical and technical adviser to the national formulary committee. Ruth is currently also Adjunct Professor of Health Policy at GW.

Dragana Baltezarevic, M.D., spec.

Dragana Baltezarevic is currently employed at the Pricing and Reimbursement Department at the Health Insurance Fund, Serbia (RFZO). She is a medical doctor. Previously she has been working at the pharmaceutical company “Hemofarm- STADA” for more than five years, as a Medical representative, Product (SBU) manager and Medical adviser at the central Portfolio Service and as a consultant for the DRG system implementation with the World Bank project “Serbia Health Project – AF”. Meanwhile, she completed postgraduate master degree at the Faculty of Pharmacy :"Pharmacoeconomics and pharmaceutical legislation". As a pricing and reimbursement specialist at the RFZO, she is responsible for analysis of the reimbursement list, pharmaceutical reimbursement strategy and drug application processing, as well as monitoring of drug utilisation. She is a member of the Subcommittees for: A, H, M, V groups and central tender Committees for: blood and blood derivates, oxygen therapy and biological therapy. She is also a member of the Committees for approving the therapy (adalimumab/infliksimab, gefitinib/erlotinib and trastazumab) as well as the Committee for Pharmacoeconomics and “off-label” use. She also carries out communication between Serbian and other HIFs through the PPRI network. Dragana enjoys practising Yoga.

Biljana Kozlovic, M.D.

Biljana Kozlovic is a medical doctor with 20 years of experience in management and consulting in pharmaceutical industry and clinical trials. She is engaged as a World Bank consultant for pharmaceuticals and procurement. As of September 2013, she holds the position of deputy director in charge of pharmaceutical affairs at Republic Health Insurance Fund in Belgrade.

Bojan Trkulja, M.D.

Bojan Trkulja, director of the Association of Manufacturers of innovative medicines INOVIA in Belgrade, Serbia from 1st December 2010. He was born in 1971 in Belgrade, where he completed his elementary, high school and medical university. After a successful intern-ship and passing the state exam, he worked in the office of F. Hoffmann - La Roche in Belgrade, from December 1999. Over the last 11 years he held a variety of positions, from associate through the Medical Product Manager, Compliance Officer and Market Access Manager.
Bojan is happily married.
Session SFE SFUS - 7th Serbian Congress of Pharmacy
Friday 12th October 2018, Crowne Plaza Hotel, Belgrade, Serbia
Is Belgrade the New Berlin?
APRIL 6, 2017
No city makes you feel more like a New Yorker than Belgrade. In Belgrade, people don’t walk, they amble; lunch spans the course of 3 or 4 hours; and drinks are sipped, never knocked back. Despite the slow pace of life, there’s still an unmistakable energy that bursts through the city.
Preliminary Program

The preliminary program for the conference "THE VALUE OF INNOVATION IN DECISION MAKING" is now available. Use the link above or access from the menu in the top right.
VI International SFE SFUS Conference
2nd June 2017, Belgrade, hotel Metropol, Serbia.

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS) is organising its Sixth International Conference with the topic:
Fifth International Conference - Speakers
9th and 10th of October 2015 Belgrade, hotel Metropol
Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden

Wija Oortwijn PhD, Partner at ECORYS NL, The Netherlands

Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland

Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK

Angela Yu MSc, London School of Economics, UK

Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank

Dávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary

Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany

Vanesa Benkovic MSc, Senior HTA and health research consultant, Croatia

Bojan Trkulja MD, Managing Director at INOVIA, Serbia

Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia, Representative of Chamber of Commerce and Industry of Serbia

Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institute, Poland

Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK

Norbert Wilk, Arcana Institute, Poland

Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia

Belgrade, 28th April 2015, hotel Crowne Plaza
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia
The objectives of the conference are:

• present the characteristics of biopharmaceutical medicines and biosimilars,

• understanding the nature of biopharmaceutical and biosimilar regulations,

• share clinical experience with biological medications and more generally

• exchanging experiences and knowledge with experts from the region and international stage.
Managed Introduction of new medicines
11 – 13 May 2015 - Warsaw, Poland
PIPERSKA workshop co-organised with the Agency for HTA & Tariff System in Poland and WHO Europe
This course is primarily intended for healthcare
professionals involved with enhancing the rational use
of medicines especially new medicines
Fifth Adriatic and Fourth Croatian Congress of Pharmacoeconomics and Outcomes Research
Šibenik, Croatia, from 23rd to 26th April 2015.
Section for Pharmacoeconomics and Outcomes Research of the Croatian Society for Clinical Pharmacology and Therapeutics, Croatian Medical Association
This year focus will be on the following subjects: 'The role and impact of pharmaceutical industry on the general economy in countries in the region' and 'The need to adapt the model for health technology assessment in countries with high risk of sustainability of healthcare financing in order to ensure transparency and competitiveness'.
5th of February 2015 Crowne Plaza Hotel, Belgrade, SERBIA
SFUS Pharmacoeconomics Section
The purpose of the Conference is to:
• Introduce and present the importance and value of patient registries,
• Introduce health outcomes and treatment outcomes reported by patients,
• Exchange experiences across the countries that used data of patients registers in the
pharmacoeconomic analysis
• Introduce the examples of special agreements (Risk sharing, Pay per Performance)
HTA for Healthcare Quality Assurance
December 15th-16th, 2014, Kraków, Poland
CEESTAHC 9th International Symposium Evidence-Based Health Care 2014